Introduction
One percent of hospital patients suffer from the noso comial pneumonia (NP) that is developed in 20% of mechan ically ventilated patients. NP increases the risk of death and requires considerable treatment expenses [1] [2] [3] [4] . The most frequent causes of NP are infections evoked by gram nega tive (Pseudomonas aeruginosa, Acinetobacter spiralis., Klebsiella spiralis. etc.) and gram positive (Staphylococcus aureus) microorganisms multiresistant to antibacterial drugs (ABD) [5] . The diversity of «problem» bacteria causing nosocomial infections and high lethality are due to inade quacy of ABD use or delay in ABD administration. These obstacles are usually circumventing by the use of evidence based regimens of treatment with those ABD that are active against most actual germs and capable to overcome resis tance mechanisms of hospital flora [6] . This is considered as a reason for a deescalation therapy [7] [8] [9] .
Clinical and economical consequences of multiresis tance of bacteria to ABD and lack of new ABD active against those pathogens stimulated the inhalationt use of ABD [10] , the efficacy of which was proved in cystic fibro sis patients [11, 12] . Inhalation allows maintaining the high concentration of the medication in the infection area [13] resulting in better bacterial killing [14, 15] and lowing both systemic absorption of medication and toxicity [16] .
Recently conducted pilot studies have demonstrat ed the efficiency of combining the systemic antibacterial therapy with inhalations. The combination therapy improved therapeutic efficacy with low toxic effects in patients [17] [18] [19] [20] [21] . Numerous studies had demonstrated the advantages of inhaled tobramycin versus intravenous mode in severe NP cases [22] [23] [24] [25] [26] .
Until today the estimation of the antibacterial therapy effectiveness is based on clinical parameters (body tempera ture, leukocytosis, somatic status) that are available for analy sis after 48-72 hours of beginning of the therapy [7, 27] . Methods of early bacterial identification in concert with the estimation of antibiotic sensitivity might have limited avail ability due to technological problems and high cost of analyz ing equipment and operating materials. The significance of Earlier studies showed an increase in LPS binding pro tein and endotoxin concentrations in patients with severe pneumonia, however, the dynamics of these molecules during the antibacterial therapy was not evaluated [28, 29] . Analysis of the arterial venous difference of gram negative bacteria LPS level might provide information on detoxifying activities of the lungs detoxicant activity as well as on the site of the gram negative infection in the pulmonary circuit. This suggestion has inspired the present study.
Goals of the study included determining the efficien cy of antibacterial therapy based on assessment of LPS con centration in venous and arterial circulations following intravenous or inhaled ABD in patients diagnosed with nosocomial pneumonia caused by gram negative bacteria.
Methods and materials
54 patients with NP associated with mechanical lung ventilation (MLV) were studied. In all cases NP was detected on ste for the first time. The diagnosis was made in accordance to the requirements of Russian National Recommendations «Nosocomial Pneumonia, adults examination», 2009. X ray scanning and computer tomography showed bilateral multisegmental character of pneumonia in all cases. Puritan Bennet 840 devices were employed for MLV in SIMV mode with volume and pressure control. In 49 patients MLV was performed following transcutaneous tracheostomy. MLV duration prior to the study was conducted for 6-11 days. At the day of diagnosis with NP patients started to receive cephalosporins (38 patients, 70,4%) or fluro quinolones (16 patients, 29,6%) as main medication. The reason for changing the therapy was the progression of NP. According to changes the patients were subdivided in two groups. First group (26 patients) included those patients treated with the traditional deescalation ther apy (intravenous injections of carbapanems). Second group of patients (28 patients) received inhalant antibiotic monotherapy (tobramycin, 300 mg every 12 hours during 10-12 days). Maximum duration of the inhaled therapy was 25 days (prescribed for a patient with the «diver trauma» due to lung destruction and high tobramycin sensitivity). Inhalations were performed with the aid of a nebulizer equipped with a bacterial filter. Inhaled tobramycin was employed as the main medica tion due to absence of other sites of infection and because of proved fast and equal diffusion through lung tissue regardless the initial ventila tion perfusion imbalance [30] . There were no cases of microflora resis tance against the applied ABD found. Initial microbiological inocula tion showed no significant difference between the groups. Patients that had gram positive microflora in culture sputum in combination with gram negative microorganisms were excluded from the study.
22 patients were transferred from intensive care departments of other hospitals. Groups were comparable in terms of etiology, severity of NP and comorbidity.
The results of bacteriological studies of bronchoalveolar lavage fluid harvested prior to therapy and received in 3-5 days showed domination of the multiresistant gram negative flora and its equal distribution in both groups. Examination by disk diffu sion revealed high sensitivity of the pathogenic microflora to car bapenemas and tobramycin ( 
Results and discussion
Prior to antibacterial therapy LPS level in both groups slightly exceeded control values (not more than 4 mcg/ml). LPS level in arterial blood was higher than in venous blood that can be explained by the high concentration of gram neg ative bacteria and bacterial decay products in the lung tissue ( changed whereas endotoxin level in arterial blood increased by several times. Four patients from the first group and seven patients from the second group had 6 fold increase of endo toxemia after changing the ABD.
The same pattern remained until the next intake that kept permanently the high difference in LPS level in arterial versus venous blood. The second intake, however, did not result in additional increase of lipopolysaccharidemia. Endotoxin content in arterial blood remained considerably high during the next 5-7 days. Arterial venous difference in LPS content had a similar timing profile with X ray and clin ical data improvements. One patient with initially low oxy genation index and excessive sputum output during the first inhalation experienced bronchospasm suppressed by bron colitic medication. In future the administration of bronchial spasmolytics and early aminophylline inhalation prevented similar complications. There was no cases of ototoxicity or nephrotoxicity when employing the inhaled tobramycin.
LPS (endotoxin, O antigen) is a membrane structural component of all gram negative bacteria [31] . The structur al alterations of a bacterial membrane results in endotoxemia since one bacteria contain up to 3 500 000 LPS molecules. High activity of carbapenems and aminoglycosides (especial ly tobramycin and amikacin) against non fermenting gram negative flora leads to rapid killing of germs [32] . This results in a release of large number of LPS molecules into microen vironment and arterial blood stream thus providing poten tial benefit to employ these consequences in developing method for express evaluation of effectiveness of antibacter ial therapy. This research is needed to be continued in terms of developing final recommendations and employing the lat ter in clinics to validate the methodology.
The fact that there was no lipopolysaccharidemia increase after the second medication intake highlights the strong antibacterial action of a prescribed first ABD.
To our knowledge, the causes of high LPS level in arterial blood remaining increased for a long time (until the regress of inflammation in the lungs), are related to the dif fusion difficulties of the antibiotic inhaled or injected into foci of lung infiltrates.
The advantageous influence of tobramycin inhalations on the arterial venous difference of LPS content can be explained by a faster germ killig effect in sputum and bronchial/alveolar microenvironment because the intra venous injections of ABD accumulation of the active sub stance there is delayed due to due to alterations of drug dis tribution in tissues. These findings have been proved indi rectly in numerous papers demonstrating clinical advantages of inhalations compared to intravenous therapy [19, 21, 33] . In our study high clinical effectiveness of the employed ther apies has been demonstrated, however, any significant proof of inhalations advantages in terms of influence on titers of microorganisms in sputum has not been achieved.
Aerosol aminoglycosides therapy is carried on easily by the patients and results in high concentration of the med ication in lung tissue. At the same time their serum concen tration is not intense [33, 34] . This improves therapy effec tiveness, its safety and decreases side effects and adverse experiences. Only few such incident have been noted in pre sent similar studies. It is unacceptable to employ intravenous and other forms of ABD for inhalations due to common com plications (bronchial and glottic spasm, coughing, damages in the mouth, gorge, trachea and bronchi, breast pain) that may defame new therapy development [35] .
It is known that after the first tobramycin inhalation its concentration in lungs of cystic fibrosis patients quickly reached maximum therapeutic means that 25 fold exceeded the minimum inhibitory concentration for Pseudomonas sp. remaining at a minimum concentration in blood [36] . The same results were collected after examination of a lung cancer patient who had been receiving inhalant tobramycin before pulmonectomy [37] . This was also true for other studied antibi otics that required high concentration of ABD for effective killing of germs [38, 39] . It is believed that further improve ments in treatment with ABD through employing the inhaled forms of ABD might stem from the decrease of proinflammato ry cytokines produced by neutrophils and macrophages (inter leukine 1β, tumor necrosis factor α etc.) as well as from the manipulating of the release of molecules of intracellular adhe sion 1 (sICAM I) reducing the neutrophilous elastase [21] . 2. Inhalations with tobramycin resulted in increased arterial lipopolysaccharidemia when compared to car bapenem deescalation therapy. This treatment was rarely complicated by side reactions and adverse events.
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